Upregulation of the peroxisome proliferator-activated receptor-alpha (PPAR alpha) with compounds such as fenofibrate has been reported to also attenuate lung inflammation36 making it a candidate of legitimate interest in the treatment of COVID-induced ARDS and associated hypercoagulability37. Here, PPARA is linked to acute respiratory distress syndrome.